Navigation Links
Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
Date:3/29/2011

;In that regard, we request that you respond to this letter no later than noon on April 1st, 2011.  I look forward to hearing from you and stand ready to answer any questions you may have.  

Very truly yours,

J. Michael Pearson
Chief Executive Officer
Valeant Pharmaceuticals International, Inc.

PRIVATE AND CONFIDENTIAL

March 25, 2011

To: The Cephalon, Inc. Board of Directors
Attention: Mr. Kevin Buchi, Chief Executive Officer and Director
41 Moores Road
Frazer, PA19355

Dear Kevin:

Thank you again for making the time to meet on March 18th to discuss Valeant's offer to buy 100% of the shares of Cephalon, Inc. ("Cephalon").  I was very disappointed to hear that you were confident that the Cephalon Board would consider our offer too low to warrant it engaging in discussions with us, especially in light of the fact that we stated that we would consider revising our offer price higher if we found additional value in non-public due diligence.  This unwillingness to engage was further reinforced by a discussion between our two bankers.  In the two meetings we have had, you have clearly stated that your shareholders are overemphasizing the upcoming patent cliffs and underestimating the inherent value of your pipeline.  We disagree and believe the market is valuing Cephalon fairly.  Therefore, we continue to believe that $73.00 per share in cash represents a compelling offer for your shareholders, for all of the reasons we described in our previous letter.

I was extremely disappointed that on Monday you announced an agreement to acquire another early-stage R&D program for $225 million in cash and other potentially significant obligations before engaging in a discussion with us regarding our offer.  You are quite aware that investments in early-stage development programs are inconsistent with our strategy and qui
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
(Date:7/30/2014)... 30, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... participate in the Jefferies 2014 Boston Healthcare Summit next ... will occur on August 6, 2014 and will not ... PDL BioPharma manages a portfolio of patents and ... antibody humanization patents and license agreements with various biotechnology ...
(Date:7/30/2014)... , 30. Juli 2014 Die ... führender Anbieter im Bereich Atemtherapie- und Druckzonenprodukte, ... Landgerichts München in Deutschland anfechten werden. Dieses ... Masken ein Patent von ResMed verletze. Apex ... wichtigen Ländern gegen verschiedene Patente von ResMed ...
Breaking Medicine Technology:Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3
... Near-Complete Mitigation of Choroidal,Neovascularization (CNV) in an AMD ... Lpath, Inc. ,the category leader in therapeutic agents ... standard animal,model of human age-related macular degeneration (AMD). ... meeting of the,Association of Research in Vision and ...
... of SEROQUEL XR--, WILMINGTON, Del., May 22, ... analyses from a large-scale,study that investigated the ... a once-daily medicine for the,treatment of schizophrenia ... annual meeting of the American Psychiatric Association,(APA). ...
Cached Medicine Technology:Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 2Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9
(Date:7/30/2014)... (PRWEB) July 30, 2014 It is said ... proved this to be true as a product sponsor ... in Las Vegas this past June. , Lash Affair ... and overall success of the eyelash industry through collaboration so ... proud to have supported NEESA ’s event. Lash Affair’s ...
(Date:7/30/2014)... mutation linked to obesity respond differently to pictures of ... not have the genetic mutation, according to a new ... Clinical Endocrinology & Metabolism ( JCEM ). , ... results from a combination of eating too much, getting ... of appetizing foods that are high in calories can ...
(Date:7/30/2014)... Texas (PRWEB) July 30, 2014 The ... (2013-18)” provides an insight into the market dynamics and ... report covers the actual and forecasted market sizing of ... various factors fuelling the demand of the same. It ... segment and major players in the market. Further, the ...
(Date:7/30/2014)... July 30, 2014 Dialogic ... today announced that DollarPhone, the largest privately owned ... the Dialogic® ControlSwitch™ softswitch to offer ... number portability (LNP) to both its wholesale and ... ControlSwitch is able to power DollarPhone’s network infrastructure, ...
(Date:7/30/2014)... HealthDay Reporter , TUESDAY, July ... might set the stage for harmful health habits, including eating ... conducted from 1982 to 2012 also found a link between ... younger a woman was when she started her first diet, ... control behaviors -- like vomiting or laxative misuse," said study ...
Breaking Medicine News(10 mins):Health News:Lash Affair Launches a New Product as Sponsor of the First U.S. Lash Extension Competition 2Health News:Brain response to appetizing food cues varies among obese people 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 2Health News:Global Pulse Oximetry Market 2018 Opportunities and Trends Now Available at MarketReportsOnline.com 3Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 2Health News:DollarPhone Expands Prepaid and Wholesale Offerings With Enhanced Dialogic ControlSwitch 3Health News:Dieting at Young Age Often Backfires, Study Says 2Health News:Dieting at Young Age Often Backfires, Study Says 3
... analysis of records of pancreatic surgery during the last ... pancreatic cancer surgeon// Charles J. Yeo, M.D., Samuel D. ... College of Thomas Jefferson University and Thomas Jefferson University ... his colleagues have revealed that contrary to what many ...
... major intestinal surgery, including stomach reduction for obesity, may ... results of the study have been published in the ... findings on three patients with increasingly poor eyesight or ... the space of a year. None of the patients ...
... A number of Canadians are more obese ... smoking less, according to a new national health survey// . ... Canada, on Tuesday, revealed that there was an underestimation ... by approximately nine per cent. The survey also indicated ...
... that a man is very critical and is suspected to have ... in a Shenzhen hospital. It is very evident that the virus ... Health Protection said that the victim lives in Shenzhen and is ... residing in Shenzhen. He fell ill after he visited a wet ...
... Families who fear the transfer of genetic diseases to their progeny ... a major NHS bank of babies' stem cells//. ,Stem ... to treat diseases such as leukemia. However cord blood banking has ... public as well as clinicians, wherein blood is taken from the ...
... warn the number of New Zealanders who take party pills ... authorities argued taking// party pills escape people from taking drugs. ... used the pill atleast once – says researchers commissioned by ... physical and psychological parts such as sleeplessness, loss of appetite, ...
Cached Medicine News:Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 2Health News:Pancreatic Cancer Surgery Successful in 80-Year-Olds 3Health News:Incidence Of Smoking Less, Obesity More, in Canada: StatsCan 2Health News:Bank of Stem Cells to Give Hope to Sick Children 2
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Nucleus manipulator used during phacoemulsification. Used to break-up the nuclues within the capsular bag during two-handed phaco techniques. Blunt round tip, angled 40 degrees, 11mm from tip. Tip an...
... effective upgrade path that allows users to ... modularity. The potential to combine two units ... a single stimulating coil. The ability to ... the power level of each Magstim 200 ...
... The Magstim Model 200 uses a ... otherwise inaccessible nerves. World market leader in ... developed by the University of Sheffield in ... cortical hemispheric and peripheral stimulation. Our best ...
Medicine Products: